Baxter International Inc. has initiated a voluntary nationwide recall for one lot of its 70% Dextrose Injection due to the potential presence of stainless steel particulate matter within the solution. This recall, announced on August 25, 2026, by the US Food and Drug Administration, addresses a significant health risk.
Intravenous administration of the affected product could lead to serious adverse health consequences. The particulate matter poses risks such as blood vessel blockage, clotting, pulmonary embolism, permanent organ damage, or even death. Additionally, patients may experience local vein irritation, inflammatory reactions, aggravated infections, and allergic responses.
As of the recall date, Baxter has not received any reports of adverse events related to this specific issue. The company is urging healthcare providers and patients to check their inventory for the recalled lot.